Correlation Between Visa and Bridge Biotherapeutics

Can any of the company-specific risk be diversified away by investing in both Visa and Bridge Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Visa and Bridge Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Visa Class A and Bridge Biotherapeutics, you can compare the effects of market volatilities on Visa and Bridge Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Visa with a short position of Bridge Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Visa and Bridge Biotherapeutics.

Diversification Opportunities for Visa and Bridge Biotherapeutics

-0.67

Correlation Coefficient

Visa  Bridge Biotherapeutics

Excellent diversification

The 3 months correlation between Visa and Bridge is -0.67. Overlapping area represents the amount of risk that can be diversified away by holding Visa Class A and Bridge Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Bridge Biotherapeutics and Visa is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Visa Class A are associated (or correlated) with Bridge Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Bridge Biotherapeutics has no effect on the direction of Visa i.e., Visa and Bridge Biotherapeutics go up and down completely randomly.

Pair Corralation between Visa and Bridge Biotherapeutics

Taking into account the 90-day investment horizon Visa Class A is expected to generate 0.17 times more return on investment than Bridge Biotherapeutics. However, Visa Class A is 5.8 times less risky than Bridge Biotherapeutics. It trades about 0.09 of its potential returns per unit of risk. Bridge Biotherapeutics is currently generating about 0.0 per unit of risk. If you would invest  20,419  in Visa Class A on September 24, 2024 and sell it today you would earn a total of  11,352  from holding Visa Class A or generate 55.6% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	97.19%
Values	Daily Returns

Visa Class A  vs.  Bridge Biotherapeutics

Visa Class A

Risk-Adjusted Performance

17 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Visa Class A are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Visa showed solid returns over the last few months and may actually be approaching a breakup point.

Bridge Biotherapeutics

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Bridge Biotherapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Bridge Biotherapeutics sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Visa and Bridge Biotherapeutics

The main advantage of trading using opposite Visa and Bridge Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Visa position performs unexpectedly, Bridge Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bridge Biotherapeutics will offset losses from the drop in Bridge Biotherapeutics' long position.

The idea behind Visa Class A and Bridge Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.